It is possible that a more potent AMPK activator such as AICAR or phenformin would be more effective at inhibition of both mTORC1 signaling and growth in Tsc2+/− cystadenoma lesions since they are also more effective in in vitro studies on TSC2-deficient fibroblasts [16]. This evidence concerns the gene TSC2 and cystadenoma.